ICU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SeaStar Medical Holding Corp (ICU) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown significant revenue growth and positive developments in its QUELIMMUNE therapy, the lack of strong trading signals, bearish technical indicators, and mixed financial performance suggest holding off on immediate investment. The investor's impatience and unwillingness to wait for optimal entry points further support this decision.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 76.009. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its resistance level of R1: 2.939. This suggests limited upside potential in the short term.
Significant revenue growth in Q4 2025 (+526.87% YoY).
Positive clinical results for QUELIMMUNE therapy published in a peer-reviewed journal.
EPS improvement (-58.61, up 553.40% YoY).
Bearish moving averages and limited short-term upside potential.
Net income remains negative (-$2.9 million in Q4 2025).
Gross margin decline (-2.86% YoY).
Analyst price target lowered from $10 to $6 due to share dilution concerns.
In Q4 2025, revenue increased to $420,000 (+526.87% YoY), driven by QUELIMMUNE sales. However, net income dropped to -$2.9 million (-34.28% YoY), and gross margin decreased to 97.14% (-2.86% YoY). EPS improved significantly to -58.61 (+553.40% YoY).
Maxim lowered the price target from $10 to $6 but maintained a Buy rating, citing positive clinical results for QUELIMMUNE therapy but factoring in share dilution concerns.
